Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lasmiditan and Sumatriptan Coadministration in Healthy Subjects
NCT03310411Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2017
- Primary completion
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of lasmiditan in migraine (4 arms), sponsored by Eli Lilly and Company. Primary endpoint: Change From Baseline in Mean 24-hour Systolic Blood Pressure at Day 2. Started Oct 2017; status: completed.
02
Drugs
lasmiditan
03
Conditions
migraine
Beyond the preview
Go deeper on NCT03310411.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03310411.